Cullinan Therapeutics is paying $20 million upfront for a BCMAxCD3 bispecific T cell engager that the biotech plans to pair ...

Zenas BioPharma has released its corporate presentation for June 2025, providing an insight into its financial and clinical ...

Patients who develop LN within 1 to 5 years after SLE onset may face poorer renal outcomes compared with those who develop the disease earlier.

The annual 10km Lupus Awareness Fun Walk took place on May 31 in Mamelodi. We Also Sparkle and Waratwa foundations held the ...

Individuals with IBD, especially CD, have an increased risk for myocardial infarction, ischemic heart disease, cerebrovascular accident, and major adverse cardiovascular events.

Belimumab, a monoclonal antibody, added to standard therapy may treat a broader range of patients with lupus nephritis than previously appreciated.

The spring meeting of the Irish Society for Rheumatology brought together experts from across Ireland and the UK to highlight ...

Cayman is launching an island-wide study to determine the prevalence of autoimmune disease lupus in the islands.

Immune cells play fundamental roles in the development, progression, and resolution of both chronic inflammatory diseases and various cancer types. In ...

Dr Li’s team concluded that “patients with SLE-TMA exhibit a progressive decline of patient and renal survival in the long-term. Prompt diagnosis and risk stratification based on identified risk ...

Living with animals is thought to have profound effects on our immunity – potentially reducing the risk of allergies, eczema ...

Three years of remission from lupus nephritis appears to be the minimum period of time that protects against impaired kidney ...